Regeneron Posts 19% Revenue Jump to $3.6B as Dupixent Powers Growth
Regeneron Pharmaceuticals (NASDAQ: REGN) reported first quarter 2026 financial results that showcased the strength of its immunology franchise, with total revenues climbing 19% year-over-year to $3.6 billion. The growth was primarily fueled by blockbuster drug Dupixent, though profitability faced headwinds from increased R&D investments and manufacturing disruptions.
Key Numbers
The pharmaceutical giant's Q1 2026 revenue of $3.605 billion marked a substantial 19% increase from $3.029 billion in the prior year quarter. GAAP diluted earnings per share came in at $6.75, down 7% from $7.27 a year ago, impacted by $0.82 per share in acquired in-process research and development charges. Non-GAAP earnings, which exclude certain items, rose 15% to $9.47 per share from $8.22.
Dupixent, Regeneron's flagship immunology drug developed with Sanofi, saw global net sales surge 33% to $4.9 billion. The company's share of Dupixent profits increased to $1.451 billion from $1.018 billion in Q1 2025, representing a 43% jump that drove collaboration revenue with Sanofi up 36% to $1.605 billion.
EYELEA HD, the company's next-generation eye medicine, posted impressive 52% growth with U.S. net sales reaching $468 million. However, combined sales of EYLEA HD and the original EYLEA formulation declined 10% to $941 million as the older product continues losing market share. EYLEA sales plummeted 36% to $473 million amid the transition to EYLEA HD and competitive pressures.
Lihtayo, the company's PD-1 inhibitor for cancer treatment, delivered standout performance with global sales jumping 54% to $438 million. U.S. sales climbed 49% to $286 million while international sales soared 63% to $152 million.
Operating expenses reflected heavy investment in the pipeline, with R&D spending up 16% to $1.544 billion on a GAAP basis. The company also faced manufacturing challenges, with gross margin on net product sales falling to 76% from 81% due to a temporary production interruption at its Limerick, Ireland facility that required unanticipated repairs.
What Management Said
CEO Leonard Schleifer highlighted the company's ability to deliver "strong double-digit growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development." He also emphasized progress on drug pricing initiatives through a new agreement with the U.S. government aimed at "promoting more balanced pricing with other wealthy nations."
CFO Christopher Fenimore struck an optimistic tone despite the earnings headwinds, noting the 19% revenue growth and 15% non-GAAP earnings growth while emphasizing the company's "balanced approach to capital allocation." He pointed to continued investment in R&D, shareholder returns through a new $3 billion share repurchase program, and preservation of financial flexibility for strategic opportunities.
Management provided important context on the manufacturing disruption, noting that production resumed at the Limerick facility in Q2 2026 and is expected to return to normal levels by the end of the second quarter. They stressed that the interruption has not impacted product availability.
On the competitive landscape for eye care, management acknowledged continued pressure on the legacy EYLEA franchise but highlighted strong physician demand for EYLEA HD, with unit demand increasing 10% sequentially despite a 7% decline in net sales due to inventory dynamics.
What to Watch
Several critical catalysts loom for Regeneron in the coming quarters. The company expects results from the Phase 3 study of fianlimab in combination with cemiplimab for first-line metastatic melanoma in Q2 2026, a key readout for its immuno-oncology pipeline.
The EYLEA HD pre-filled syringe approval remains pending, with management anticipating FDA decisions on one or both manufacturing applications during Q2 2026. This approval could significantly enhance the product's competitive position and ease of use.
Investors should monitor the normalization of gross margins as the Limerick facility returns to full production capacity by the end of Q2. The temporary disruption's impact on profitability should dissipate, potentially providing a tailwind to earnings in the second half of 2026.
The recent FDA approval of EYLEA HD for extended dosing intervals up to 5 months could accelerate market share gains from competitors and the original EYLEA formulation. This represents the widest dosing interval of any injectable anti-VEGF product, a significant competitive advantage.
Longer term, Regeneron's deep pipeline of nearly 50 clinical programs provides multiple shots on goal, with particular focus on the Factor XI anticoagulation program entering Phase 3 development and cemdisiran for myasthenia gravis approaching potential FDA approval in Q4 2026.
The company's new pricing agreement with the U.S. government, while potentially constraining pricing power, provides regulatory certainty and exemption from future government pricing mandates for three years—a strategic trade-off that management views as beneficial for long-term planning.
*StockCliff Research*